About us
Cancer Research Horizons is a wholly owned subsidiary of Cancer Research UK, acting as its translational arm to advance bold research innovations.
We operate at the interface between research and industry to accelerate the translation of innovative science into treatments and diagnostics for patients around the world.
Who we are
We're here to make the most of research that could benefit patients, by helping advance, develop and commercialise innovations.
By uniting our in-house drug discovery and development expertise and Cancer Research UK's network of researchers and clinicians with cutting-edge technology, partners and investment, we're bridging the gap to bring new treatments to patients faster.
Our purpose is to beat cancer
Our mission
We bring together the brightest minds, boldest ideas and best partners to fast-track scientific breakthroughs for patient benefit.
Our vision
To bring forward the day when all cancers are conquered.
Our people
Our specialist teams are at the heart of everything we do. From Therapeutic Innovation to Commercial Partnerships, meet the experts fast-tracking scientific breakthroughs into patient benefit.
Research, infrastructure and partnerships
With exclusive rights to over £400m of Cancer Research UK's world-class cancer research each year, we have unparalleled access to the UK's best science.
Our network of 200 drug discovery scientists across six sites in the UK also offers researchers and partners access to the full spectrum of drug discovery from early stage concepts to development of class-leading cancer drugs.
Through our global network of industry, investor and research partners, we're turning more discoveries into effective tools, treatments and diagnostics.
Annual reviews
Read our latest annual review showcasing how we're leveraging our extensive commercialisation and drug discovery expertise to translate Cancer Research UK’s research outputs into patient and public benefit.
Do you want to help bring forward the day when all cancers are conquered?
We want to hear from researchers, entrepreneurs, partners and investors.